Skip to main content
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. — Investor Relations & Filings

Ticker · PTHS ISIN · US1711261057 US Manufacturing
Filings indexed 205 across all filing types
Latest filing 2024-06-19 Director's Dealing
Country US United States of America
Listing US PTHS

About Pelthos Therapeutics Inc.

https://ir.pelthos.com/

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products for patients with unmet medical needs. Its lead product is ZELSUVMI™ (berdazimer topical gel, 10.3%), the first FDA-approved, at-home prescription treatment for molluscum contagiosum. ZELSUVMI is based on the company's proprietary nitric oxide-releasing technology platform, NITRICIL™, which is also being utilized for a pipeline of other product candidates. The company's portfolio also includes the acquired asset Xepi (ozenoxacin) Cream, 1%.

Recent filings

Filing Released Lang Actions
Director's Dealing 2024
Director's Dealing
2024-06-19 English
Director's Dealing 2024
Director's Dealing
2024-06-19 English
Director's Dealing 2024
Director's Dealing
2024-06-19 English
424B3
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q quarterly report filed with the SEC for the quarter ended March 31, 2024. It contains detailed unaudited financial statements including balance sheets, statements of operations, changes in stockholders' equity, cash flows, and management's discussion and analysis. The presence of comprehensive financial data and the explicit labeling as a quarterly report on Form 10-Q confirms this classification. The document length is substantial (15,000 characters), indicating it is the full report, not just an announcement or supplement. Therefore, the correct classification is Interim / Quarterly Report (IR).
2024-05-15 English
424B3
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q quarterly report filed by Chromocell Therapeutics Corporation for the quarter ended March 31, 2024. It contains detailed unaudited financial statements including balance sheets, statements of operations, changes in stockholders' equity, and cash flows, as well as management's discussion and analysis and other required disclosures. The presence of comprehensive financial data and the specific SEC form designation (10-Q) clearly identify this as an Interim / Quarterly Report. The document length (15,000 characters) and content confirm it is the report itself, not merely an announcement or certification. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report).
2024-05-15 English
10-Q
Interim / Quarterly Report Q1 2024
2024-05-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.